The essence in brief:

Craniopharyngiomas are diagnosed through magnetic resonance imaging (MRI) and are typically treated with surgical intervention. As the tumor grows, it can compress the pituitary gland, resulting in the deficiency of certain hormones or complete pituitary insufficiency. Hormone replacement therapy may be necessary to address these deficiencies.

Human life begins with a stem cell called the zygote. The cells divide, and around the sixth day, a blastocyst forms. Cells inside this cyst can no longer differentiate into a complete human being but lack the ability to produce the cell types of the body, such as heart cells, muscle cells, or nerves.

In further stages of development, two cell layers initially form. These cell layers are called embryonic germ layers. The outer cell layer is called the ectoderm, and the inner layer is called the endoderm. A third layer, the mesoderm, later forms between these cell layers. In the embryo, the anterior pituitary gland develops from an outgrowth of the roof of the pharynx. This outgrowth is called Rathke’s pouch. Rathke’s pouch, like the brain, is of ectodermal origin. A developmental tumor can arise from ectodermal remnants of Rathke’s pouch in the sella or adjacent to the sella.

Diagnosis

A craniopharyngioma is diagnosed through magnetic resonance imaging (MRI).

Therapy

There is no medication-based therapy for craniopharyngiomas. Surgical intervention is performed when the tumor increases in size.

Due to the growth of the craniopharyngioma, there is compression of the pituitary gland, leading to the deficiency of specific pituitary hormones or complete pituitary insufficiency. The deficient hormones need to be replaced, as described in the section on pituitary insufficiency.